RUA BIOSCIENCE LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.047 NZD | -4.08% |
|
-6.00% | -60.83% |
| 07/05 | Rua Bioscience Extends Distribution Agreement with Germany's Nimbus Health | MT |
| 07/05 | Rua Bioscience Limited Extends Agreement with Nimbus Health in Germany | CI |
| Sales 2022 | 6L 4L 3.3Cr | Sales 2023 | 7L 4L 3.42Cr | Capitalization | 2.44Cr 1.49Cr 124.42Cr |
|---|---|---|---|---|---|
| Net income 2022 | -80L -48.98L -41Cr | Net income 2023 | -50L -30.61L -26Cr | EV / Sales 2022 | 62.5 x |
| Net cash position 2022 | 91.15L 55.8L 47Cr | Net cash position 2023 | 44.47L 27.23L 23Cr | EV / Sales 2023 | 29.8 x |
| P/E ratio 2022 |
-5.5
x | P/E ratio 2023 |
-3.85
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 52.95% |
More Fundamentals
* Assessed data
More news
| 1 day | -4.08% | ||
| 1 week | -6.00% | ||
| Current month | -32.86% | ||
| 1 month | -32.86% | ||
| 3 months | -36.49% | ||
| 6 months | -59.13% | ||
| Current year | -60.83% |
1 week
0.05
0.05
1 month
0.050.07
Current year
0.050.12
1 year
0.050.17
3 years
0.050.53
5 years
0.050.75
10 years
0.050.75
| Managers | Title | Age | Since |
|---|---|---|---|
Paul Naske
CEO | Chief Executive Officer | - | 01/19/01 |
Manu Caddie
FOU | Founder | - | 01/16/01 |
Liam Walker
DFI | Director of Finance/CFO | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anthony Barclay
BRD | Director/Board Member | - | 01/23/01 |
Anna Stove
CHM | Chairman | - | 01/19/01 |
| Director/Board Member | - | 01/22/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/24/24 | 0.047 | -4.08% | 16,976 |
| 21/24/21 | 0.049 | 0.00% | 81,503 |
| 20/24/20 | 0.049 | -2.00% | 24,569 |
| 19/24/19 | 0.05 | -1.96% | 21,335 |
| 18/24/18 | 0.051 | +2.00% | 40,739 |
End-of-day quote New Zealand S.E., June 24, 2024
More quotes
Rua Bioscience Limited is a New Zealand-based medicinal cannabis company. The Company is engaged in the business of research and development, and pharmaceutical distribution and marketing. The Company is focused on breeding, cultivating, manufacturing, and supplying medicinal cannabis. The Company operates through one segment: research and development and the sale of pharmaceutical products in Germany and New Zealand. The Company supplies Good Manufacturing Practice (GMP)-certified medicines to expanding markets, supported by international supply agreements in Europe and an Australian partnership for GMP-certified products.
Sector
Pharmaceuticals
Calendar
26/08/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -60.83% | 46.02L | |
| +29.76% | 567.79Cr | |
| -32.34% | 359.29Cr | |
| 0.00% | 312.11Cr | |
| -25.09% | 262.41Cr | |
| -10.35% | 230.16Cr | |
| +41.50% | 188.09Cr | |
| +40.90% | 145.13Cr | |
| -15.16% | 139.36Cr | |
| +42.86% | 137.25Cr |
- Stock Market
- Equities
- RUA Stock
